Ligand PharmaceuticalsFRA:LGDN +3.88%80 FCF Margin % is 93.70% as of Mar. 2026, which is 174% above its 10-year median of 34.23. GuruFocus rates FRA:LGDN with a GF Score™ of 80/100 and a GF Value™ of €150.35 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 956 Biotechnology companies, Ligand Pharmaceuticals ranks better than 95.61% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LGDN vs DFTX, CGON, XENE: FCF Margin % Comparison
For the Biotechnology subindustry, Ligand Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ligand Pharmaceuticals FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Ligand Pharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ligand Pharmaceuticals (FRA:LGDN) has a FCF Margin % of 93.70% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Ligand Pharmaceuticals and its competitors. This is 174% above median its historical median of 34.23. According to the industry distribution chart, Ligand Pharmaceuticals ranks #42 out of 956 companies in the Biotechnology industry, placing it in the top 4.4%.
Is Ligand Pharmaceuticals' FCF Margin % too high?
Ligand Pharmaceuticals' current FCF Margin % of 93.70% is 174% above median its 10-year median of 34.23. Based on the distribution chart, Ligand Pharmaceuticals ranks #42 out of 956 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ligand Pharmaceuticals has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ligand Pharmaceuticals' FCF Margin % compare to DFTX and CGON?
According to the Biotechnology industry distribution chart, Ligand Pharmaceuticals ranks #42 out of 956 companies for FCF Margin %. This places Ligand Pharmaceuticals in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Ligand Pharmaceuticals and its competitors. Ligand Pharmaceuticals's current FCF Margin % is 93.70%, which is 174% above median its own 10-year median of 34.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ligand Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ligand Pharmaceuticals (FRA:LGDN) is currently considered Significantly Overvalued. The stock's GF Value™ is €150.35, compared to a current price of €268.00 — trading 78.3% above its estimated fair value. The current FCF Margin % is 93.70%, which is 174% above median its 10-year median of 34.23. Ligand Pharmaceuticals' overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Ligand Pharmaceuticals (FRA:LGDN), the current FCF Margin % is 93.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ligand Pharmaceuticals (FRA:LGDN) Overvalued in 2026?
Based on GuruFocus' analysis, Ligand Pharmaceuticals stock appears to be overvalued.
The current stock price of €268.00 is trading 78.3% above its estimated GF Value™ of €150.35.
GuruFocus considers Ligand Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:LGDN:
FCF Margin %: 93.70% (174% above median its 10-year median of 34.23)
GF Value™: €150.35 vs. price of €268.00 (78.3% above fair value)
No single metric tells the full story. See the FRA:LGDN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
80GF Score
Get the complete analysis for FRA:LGDN
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LGDN has been successfully added to your 
